Answers are grounded in this paper and cite their sources.
KRAS mutational analysis is a genetic test used in clinical practice for determining the status of the KRAS gene (wild type or mutant) in tumors from patients with metastatic colorectal cancer (CRC). Persons whose tumors are wild type may respond to therapies cetuximab (Erbitux) or panitumumab (Vectibix).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: